AZD8835

AZD8835 is an orally bioavailable small molecule inhibitor that selectively targets the class I phosphatidylinositol 3‑kinase (PI3K) catalytic subunit alpha (PIK3CA) and delta (PIK3CD), with high potency against both isoforms. By inhibiting PIK3CA and its mutated forms within the PI3K/Akt/mTOR signaling pathway—a pathway frequently deregulated in human cancers—AZD8835 induces apoptosis and inhibits growth in PIK3CA-expressing tumor cells. This selectivity may offer improved efficacy and reduced toxicity compared to pan‑PI3K inhibitors. The drug has been primarily developed for solid tumors harboring activating mutations in the PI3K pathway and has shown antitumor activity both as monotherapy and in combination with other targeted agents such as fulvestrant. It also demonstrates immunomodulatory effects by promoting CD8+ T-cell activation independent of regulatory T-cell suppression[1][2][6][7][8].

Other names

1620576-64-81-(4-(5-(5-Amino-6-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one